Arkolith/Insider Trading/SYRS/Form 4

Stephens Kristin

Chief Development OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Nov 20, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8K
Net Open-Market Flow
-$8K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 18, 2024Sell(S)36K$0.22$8K0

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-129384) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML